Mostrando 3 resultados de: 3
Anti-EGF antibodies as surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimized CIMAvax-EGF vaccination schedule
ArticleAbstract: We previously reported that CIMAvax-EGF vaccine is safe, immunogenic and efficacious to treat advancPalabras claves:antibodies affinity, cancer vaccine, EGF, NSCLC, surrogate biomarkerAutores:Alvarez K., Carmen Elena Viada, Fuentes K.P., García Verdecia B., González A., Gonzalez Z., Huerta V., Mazorra Z., Neninger Vinageras E., Popa X., Rodríguez P.C., Tania CrombetFuentes:scopusA randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients
ArticleAbstract: Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated gangliPalabras claves:Autores:Alfonso S., Areces F., Carmen Elena Viada, Cepeda M., Chong E., De La Torre A.V., Flores Y.I., García E., Gonzalez Z., Guerra P.P., Hernández A.M., Hernández M., Macías A.E., Mazorra Z., Mendoza I.C., Ortiz R.A., Pérez K., Pérez R., Santiesteban E.R., Tania Crombet, Toledo D., Valdes-Zayas A., Vázquez A.M.Fuentes:scopusNimotuzumab induces NK cell activation, cytotoxicity, dendritic cell maturation and expansion of EGFR-specific T cells in head and neck cancer patients
ArticleAbstract: Survival benefit and long-term duration of clinical response have been seen using the epidermal growPalabras claves:head and neck cancer, Human epidermal growth factor receptor, monoclonal antibodies, Natural killer cells, T cellsAutores:Barroso M.C., Concha-Benavente F., Cuevas I., Ferris R.L., Frómeta C., García-Bates T.M., González A., Gonzalez Z., Hechavarría E., Lavastida A., Lugiollo M., Mazorra Z., Mestre B.F., Srivastava R.M., Tania Crombet, Valdés A.Fuentes:scopus